| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ZSTK474 | GDSC1000 | pan-cancer | AAC | 0.08 | 0.02 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.09 | 0.02 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.02 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.091 | 0.02 |
| mRNA | phloretin | CTRPv2 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.081 | 0.02 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | VER-155008 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.02 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.082 | 0.02 |